TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Xxlofoten AS
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
3,341
|
2,484
|
2,278 |
| Financial expenses |
39
|
38
|
30 |
| Earnings before taxes |
375
|
453
|
438 |
| Total assets |
2,258
|
1,885
|
2,468 |
| Current assets |
1,508
|
969
|
1,223 |
| Current liabilities |
1,308
|
683
|
166 |
| Equity capital |
435
|
579
|
1,578 |
| - share capital |
313
|
330
|
352 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
19.3%
|
30.7%
|
63.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
11.2%
|
18.2%
|
19.2% |
| Return on assets (ROA) |
18.3%
|
26.0%
|
19.0% |
| Current ratio |
115.3%
|
141.9%
|
736.7% |
| Return on equity (ROE) |
86.2%
|
78.2%
|
27.8% |
| Change turnover |
984
|
351
|
793 |
| Change turnover % |
42%
|
16%
|
53% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.